AMAG Pharmaceuticals, Inc. to Present at the Deutsche Bank 2008 Biotech Boston Confab

AMAG Pharmaceuticals, Inc. (NASDAQ: AMAG) today announced that Brian J.G. Pereira, MD, President and Chief Executive Officer, will present an overview of the Company at the Deutsche Bank 2008 Biotech Boston Confab on November 11, 2008 at 9:40 a.m. ET. The conference will take place in Boston.

A live audio webcast of the presentation will be accessible through the Investors section of the Company’s website at www.amagpharma.com. Following the conference, the webcast will be archived on the AMAG Pharmaceuticals, Inc. website until November 25, 2008.

About AMAG Pharmaceuticals, Inc.

AMAG Pharmaceuticals, Inc. is a biopharmaceutical company that utilizes its proprietary technology for the development and commercialization of a therapeutic iron compound to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.

Ferumoxytol is being developed for use as an intravenous iron replacement therapeutic agent for the treatment of iron deficiency anemia and as a diagnostic agent for vascular-enhanced magnetic resonance imaging to assess peripheral arterial disease. In December 2007, the Company submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for marketing approval of ferumoxytol as an intravenous iron replacement therapy in chronic kidney disease patients. In October 2008, the Company received a Complete Response Letter from the FDA with respect to its NDA requesting certain additional information prior to the approval of ferumoxytol for marketing and sale in the U.S.